Jeff Garro
Stock Analyst at Stephens & Co.
(1.16)
# 3,373
Out of 4,814 analysts
49
Total ratings
33.33%
Success rate
-12.78%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Reiterates: Equal-Weight | $28 | $24.39 | +14.80% | 3 | Apr 10, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $220.66 | +26.89% | 2 | Mar 6, 2025 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $7 → $5 | $3.85 | +29.87% | 4 | Mar 6, 2025 | |
| CERT Certara | Reiterates: Overweight | $17 | $14.15 | +20.14% | 5 | Feb 27, 2025 | |
| EVH Evolent Health | Maintains: Equal-Weight | $16 → $12 | $8.97 | +33.78% | 5 | Jan 21, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $26 | $23.68 | +9.80% | 3 | Jan 7, 2025 | |
| DH Definitive Healthcare | Initiates: Equal-Weight | $5 | $2.53 | +98.02% | 1 | Dec 20, 2024 | |
| DOCS Doximity | Initiates: Equal-Weight | $55 | $53.20 | +3.38% | 1 | Dec 20, 2024 | |
| OPRX OptimizeRx | Initiates: Equal-Weight | $5.5 | $8.46 | -34.99% | 3 | Dec 20, 2024 | |
| IQV IQVIA Holdings | Initiates: Overweight | $250 | $143.91 | +73.72% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $14.38 | +18.26% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $32.66 | +19.43% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 | $23.94 | +16.96% | 8 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $6.83 | +309.96% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $19.43 | +2.93% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $2.73 | +42.86% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.24 | -7.41% | 3 | May 6, 2022 |
TruBridge
Apr 10, 2025
Reiterates: Equal-Weight
Price Target: $28
Current: $24.39
Upside: +14.80%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $220.66
Upside: +26.89%
Health Catalyst
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.85
Upside: +29.87%
Certara
Feb 27, 2025
Reiterates: Overweight
Price Target: $17
Current: $14.15
Upside: +20.14%
Evolent Health
Jan 21, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $8.97
Upside: +33.78%
Privia Health Group
Jan 7, 2025
Reiterates: Overweight
Price Target: $26
Current: $23.68
Upside: +9.80%
Definitive Healthcare
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5
Current: $2.53
Upside: +98.02%
Doximity
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $53.20
Upside: +3.38%
OptimizeRx
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5.5
Current: $8.46
Upside: -34.99%
IQVIA Holdings
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $143.91
Upside: +73.72%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $14.38
Upside: +18.26%
Nov 15, 2024
Initiates: Overweight
Price Target: $39
Current: $32.66
Upside: +19.43%
May 31, 2024
Reiterates: Overweight
Price Target: $28
Current: $23.94
Upside: +16.96%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $6.83
Upside: +309.96%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $19.43
Upside: +2.93%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $2.73
Upside: +42.86%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $3.24
Upside: -7.41%